◐ Shell
reader mode source ↗
Jump to content
Edit links
From Wikipedia, the free encyclopedia
Pharmaceutical compound
2C-G-3
Clinical data
Other names2,5-Dimethoxy-3,4-(trimethylene)phenethylamine; 3,4-Trimethylene-2,5-dimethoxyphenethylamine; 3,4-Trimethylene-2,5-DMPEA
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action12–24 hours[1]
Identifiers
  • 2-(4,7-dimethoxy-2,3-dihydro-1H-inden-5-yl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H19NO2
Molar mass221.300 g·mol−1
3D model (JSmol)
  • COC1=C2CCCC2=C(C(=C1)CCN)OC
  • InChI=1S/C13H19NO2/c1-15-12-8-9(6-7-14)13(16-2)11-5-3-4-10(11)12/h8H,3-7,14H2,1-2H3
  • Key:DUYSKWSFDDDWQI-UHFFFAOYSA-N

2C-G-3, also known as 2,5-dimethoxy-3,4-(trimethylene)phenethylamine, is a psychedelic drug of the phenethylamine and 2C families.[1] It is the derivative of 2C-G (2C-G-0) in which the 3,4-dimethyl groups have been connected via an additional carbon atom to form a cyclopentane ring attached to the benzene ring and hence has a dihydroindene ring system.[1]

In his 1991 book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 2C-G-3's dose as 16 to 25 mg orally and its duration as 12 to 24 hours.[1][2][3] The effects of 2C-G-3 were reported to include "lots of LSD-like sparkles", easier communication, impairment, and social avoidance, among others.[1] One report remarked that it was "marvelous".[1]

The chemical synthesis of 2C-G-3 has been described.[1]

The drug was first described in the literature by Shulgin in PiHKAL in 1991.[1] It is a controlled substance in Canada under phenethylamine blanket-ban language.[4]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 9 Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. https://erowid.org/library/books_online/pihkal/pihkal028.shtml
  2. ↑ Jacob P, Shulgin AT (1994). "Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.). Hallucinogens: An Update (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91. PMID 8742795. Archived from the original on 13 July 2025.
  3. ↑ Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.
  4. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=2C-G-3&oldid=1339961960"